Previous 10 | Next 10 |
home / stock / mrna / mrna articles
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adu...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moder...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moder...
On CNBC's “Mad Money Lightning Round,” Jim Cramer called Celestica Inc. (NYSE:CLS) “terrific” after the Toronto-based ...
These large-cap stocks were the best performers in the last week. Are they in your portfolio? First Solar, Inc. (NASDAQ:FSLR) shares jumped 41.5%...
Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases ...
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results...
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of Analog Devices, Inc. (NASDAQ:ADI) rose s...
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Oracle Corporation (NYSE:ORCL) as his final trade...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...